Journal Watch: Antigen dose-response reevaluation

Mon Sep 28 08:14:21 EST 1992

Journal Watch (JW)

  Has anyone noticed the subtle reevaluation of quantitative aspects of
lymphocyte signalling over the last few months?

  (i) Williams and Beyers. Nature 356, 746-747 state: "It is generally
thought that TCRs must be crosslinked to activate a T cell, yet how is
this to occur through the TCR:MHCpep interaction? It seems most
improbable that adjacent MHC molecules will display the same peptides,
and to give a cross-linking signal two MHC molecules displaying the same
peptide would have to be tethered together."

 (ii)Tamura and Nariuchi. J. Immunology 148, 2370-2377 state: "These
results indicate that monovalent anti-CD3 is more efficient than divalent
anti-CD3 in induction of IL2 production and that cross-linkage of the
TCR/CD3 complex is not necessarily required for T cell clone activation."

(iii)Ucker, Meyers and Obermiller J. Immunology 149, 1583-1592 state:
"At low stimulatory dose [of antigen], cells do not respond but they
remain viable for extended periods. At higher dose (operationally in the
normal range), cells proliferate in a dose-dependent fashion. Finally,
at still higher dose, proliferation is inhibited and cells rapidly
become non-viable."  "In the simplest sense, it is possible to model the
cellular response as a function of the dose or strength of stimulation. One
high dose of stimulus gives proliferation, two give cell death."

  Any comments?
                         Don Forsdyke (Discussion leader)

More information about the Immuno mailing list